Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Human Papillomavirus-Related Carcinoma: early-phase trial registry

2 of 8 indexed Human Papillomavirus-Related Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

8 US clinical trials · 2 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Human Papillomavirus-Related Carcinoma: 8 US clinical trials tracked, 2 recruiting.

Human Papillomavirus-Related Carcinoma is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.

Enrollment posture brief

Registry condition human-papillomavirus-related-carcinoma

OPEN 2 | RECR 25% | LATE 0 | EARLY 6 | RANK #2176 | SPON 3

Volume-matched condition peers

Nearest open-share peer: Abdominal Pain (25% recruiting · 20 trials)

Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%Human Papillomavirus-Rel (th…25%
Open-enrollment share among volume-matched conditions near Human Papillomavirus-Related Carcinoma

Human Papillomavirus-Related Carcinoma lists 2 open slots (25% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Human Papillomavirus-Related Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Human Papillomavirus-Related Carcinoma is recruiting below its size-band peers.

    2 of 8 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Human Papillomavirus-Related Carcinoma research.

    National Cancer Institute (NCI) accounts for 3 of 8 trials (37.5%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Human Papillomavirus-Related Carcinoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 51 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.

  4. Human Papillomavirus-Related Carcinoma research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 22

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2

Top Sponsors

National Cancer Institute (NCI) 3 trials
Emory University 1 trials
Baylor College of Medicine 1 trials
M.D. Anderson Cancer Center 1 trials
University of Michigan 1 trials
University of Texas Southwestern Medical Center 1 trials

Named interventions

Most-linked intervention names on Human Papillomavirus-Related Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Recombinant Human Papillomavirus Nonavalent Vaccine Biological
3 trials
Questionnaire Administration Other
2 trials
Biospecimen Collection Procedure
2 trials
Hypofractionated intensity modulated radiotherapy Radiation
1 trials
MeFirst Tailored Intervention Behavioral
1 trials
HPV Self-Collection Procedure
1 trials
HPV Specific T Cells Genetic
1 trials
Internal Radiation Therapy Radiation
1 trials

US sites by state

Facility locations filed on Human Papillomavirus-Related Carcinoma trials. A trial with sites in several states counts in each.

Texas 3 trials
California 2 trials
Alabama 2 trials
Wisconsin 1 trials
New York 1 trials
North Carolina 1 trials
Minnesota 1 trials
Michigan 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Human Papillomavirus-Related Carcinoma page

8 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Human Papillomavirus-Related Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • National Cancer Institute (NCI) sponsors the most Human Papillomavirus-Related Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Human Papillomavirus-Related Carcinoma condition card totals 8 registered trials; most-linked intervention Recombinant Human Papillomavirus Nonavalent Vaccine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.